101 related articles for article (PubMed ID: 18923852)
1. Rational design of antithrombotic peptides to target the von Willebrand factor (vWf)--GPIb integrin interaction.
Munoz Cdel C; Campbell W; Constantinescu I; Gyongyossy-Issa MI
J Mol Model; 2008 Dec; 14(12):1191-202. PubMed ID: 18923852
[TBL] [Abstract][Full Text] [Related]
2. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
Azzam K; Cissé-Thiam M; Drouet L
Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
[TBL] [Abstract][Full Text] [Related]
3. Identification of peptide antagonists to glycoprotein Ibalpha that selectively inhibit von Willebrand factor dependent platelet aggregation.
Benard SA; Smith TM; Cunningham K; Jacob J; DeSilva T; Lin L; Shaw GD; Kriz R; Kelleher KS
Biochemistry; 2008 Apr; 47(16):4674-82. PubMed ID: 18363340
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
[TBL] [Abstract][Full Text] [Related]
5. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity.
Barstad RM; Stephens RW; Hamers MJ; Sakariassen KS
Thromb Haemost; 2000 Feb; 83(2):334-7. PubMed ID: 10739395
[TBL] [Abstract][Full Text] [Related]
6. Crotalin, a vWF and GP Ib cleaving metalloproteinase from venom of Crotalus atrox.
Wu WB; Peng HC; Huang TF
Thromb Haemost; 2001 Dec; 86(6):1501-11. PubMed ID: 11776320
[TBL] [Abstract][Full Text] [Related]
7. Evidence from limited proteolysis of a ristocetin-induced conformational change in human von Willebrand factor that promotes its binding to platelet glycoprotein Ib-IX-V.
Kang M; Wilson L; Kermode JC
Blood Cells Mol Dis; 2008; 40(3):433-43. PubMed ID: 17977030
[TBL] [Abstract][Full Text] [Related]
8. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain.
Huizinga EG; Tsuji S; Romijn RA; Schiphorst ME; de Groot PG; Sixma JJ; Gros P
Science; 2002 Aug; 297(5584):1176-9. PubMed ID: 12183630
[TBL] [Abstract][Full Text] [Related]
9. A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation.
Hauert J; Fernandez-Carneado J; Michielin O; Mathieu S; Grell D; Schapira M; Spertini O; Mutter M; Tuchscherer G; Kovacsovics T
Chembiochem; 2004 Jun; 5(6):856-64. PubMed ID: 15174170
[TBL] [Abstract][Full Text] [Related]
10. Structure and function of snake venom toxins interacting with human von Willebrand factor.
Matsui T; Hamako J
Toxicon; 2005 Jun; 45(8):1075-87. PubMed ID: 15922776
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effect of a protein-type I class snake venom metalloproteinase, kistomin, is mediated by affecting glycoprotein Ib-von Willebrand factor interaction.
Hsu CC; Wu WB; Chang YH; Kuo HL; Huang TF
Mol Pharmacol; 2007 Oct; 72(4):984-92. PubMed ID: 17609416
[TBL] [Abstract][Full Text] [Related]
12. High shear stress attenuates agonist-induced, glycoprotein IIb/IIIa-mediated platelet aggregation when von Willebrand factor binding to glycoprotein Ib/IX is blocked.
Iijima K; Murata M; Nakamura K; Kitaguchi T; Handa M; Watanabe K; Fujimura Y; Yoshioka A; Ikeda Y
Biochem Biophys Res Commun; 1997 Apr; 233(3):796-800. PubMed ID: 9168936
[TBL] [Abstract][Full Text] [Related]
13. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(alpha)-vWF tether bond.
Doggett TA; Girdhar G; Lawshé A; Schmidtke DW; Laurenzi IJ; Diamond SL; Diacovo TG
Biophys J; 2002 Jul; 83(1):194-205. PubMed ID: 12080112
[TBL] [Abstract][Full Text] [Related]
14. [Determination of the detachment force of platelet membrane protein GPIb/IX and von Willebrand factor].
Wang Y; Gao Z; Hu Y; Hu Q; Yang C; Zhuang F
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Jun; 26(3):590-4, 605. PubMed ID: 19634679
[TBL] [Abstract][Full Text] [Related]
15. Differential aspects of the glycoprotein Ib-von Willebrand factor axis in human and pig species.
Zurbano MJ; Escolar G; Heras M; Ordinas A; Castillo R
Haematologica; 2000 May; 85(5):514-9. PubMed ID: 10800169
[TBL] [Abstract][Full Text] [Related]
16. Structure-function relationship of the A1 domain of von Willebrand factor.
Girma JP; Ribba AS; Meyer D
Thromb Haemost; 1995 Jul; 74(1):156-60. PubMed ID: 8578449
[TBL] [Abstract][Full Text] [Related]
17. Guinea pig blood: a model for the pharmacologic modulation of the GPIb/IX-vWF axis.
André P; Hamaud P; Bal dit Sollier C; Drouet V; Garfinkel LI; Uzan A; Caen JP; Drouet LO
Thromb Res; 1996 Jul; 83(2):127-36. PubMed ID: 8837311
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis.
Kroner PA; Frey AB
Biochemistry; 1996 Oct; 35(41):13460-8. PubMed ID: 8873615
[TBL] [Abstract][Full Text] [Related]
19. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin.
Patzke J; Budde U; Huber A; Méndez A; Muth H; Obser T; Peerschke E; Wilkens M; Schneppenheim R
Blood Coagul Fibrinolysis; 2014 Dec; 25(8):860-70. PubMed ID: 25192242
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V.
Gresele P; Momi S
Handb Exp Pharmacol; 2012; (210):287-309. PubMed ID: 22918736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
